Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Accrued expenses and other long-term liabilities, excluding National, consisted of the following ($ in thousands):

	December 31,
($ in thousands)	2016		2015
Accrued expenses:
Professional fees	$	1,253	$	382
Salaries, bonuses and related benefits		2,846		2,492
Accrued Severance		53
Ovamed manufacturing rights - short term component		900		2,007
Research and development		394		303
Dr. Falk Pharma milestone		2,634		2,717
JMC accrued cost of goods sold		726		-
Lease impairment		128		146
Other		1,148		523
Total accrued expenses	$	10,082	$	8,570

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		5,014		584
Total other long-term liabilities	$	5,014	$	584

National's accounts payable and other accrued expenses as of September 30, 2016, consisted of the following ($ in thousands):

	September 30,
	2016
Legal	$	1,346
Audit		198
Telecommunications		209
Data Services		425
Regulatory		444
Settlements		832
Deferred rent		65
Contingent consideration payable		424
Other		3,223
Total	$	7,166